Yen FS, Wei JCC, Liu JS, et al. - Since people with young-onset diabetes (YOD) show a higher risk of morbidity and mortality than those with late-onset diabetes, researchers sought to compare the risks of hospitalization and mortality among people with YOD to whom second-line oral antidiabetic drugs (OADs) were administered. Between 2009 and 2014, 7,257 people were enrolled in a study that used second-line OADs after first-line metformin therapy. Taking add-on DPP-4 inhibitors was associated with lower risks of all-cause hospitalization and mortality in people with YOD than taking add-on sulfonylureas. DPP-4 inhibitors appear to be an appropriate second-line OAD for such patients.